Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Indolent B-Cell Non-Hodgkin Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT00093769
What this trial is testing

Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Jonsson Comprehensive Cancer Center 15
Testing effectiveness (Phase 2)Study completedNCT00980395
What this trial is testing

Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma

Who this might be right for
LymphomaMantle Cell LymphomaIndolent Lymphoma+1 more
University of Arizona 24
Testing effectiveness (Phase 2)Study completedNCT03105336
What this trial is testing

Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Who this might be right for
Follicular LymphomaMarginal Zone LymphomaIndolent Non-Hodgkin Lymphoma
Kite, A Gilead Company 159
Testing effectiveness (Phase 2)Ended earlyNCT01799889
What this trial is testing

Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Chronic Lymphocytic LeukemiaMantle Cell LymphomaDiffuse Large B-cell Lymphoma+2 more
Gilead Sciences 326
Early research (Phase 1)Study completedNCT00058227
What this trial is testing

Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma

Who this might be right for
B-cell Chronic Lymphocytic LeukemiaContiguous Stage II Grade 1 Follicular LymphomaContiguous Stage II Grade 2 Follicular Lymphoma+40 more
National Cancer Institute (NCI) 37
Testing effectiveness (Phase 2)Active Not RecruitingNCT05202782
What this trial is testing

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma Associated With Chronic InflammationEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma, Not Otherwise Specified+16 more
Northwestern University
Early research (Phase 1)Study completedNCT02242045
What this trial is testing

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL)

Who this might be right for
Chronic Lymphocytic LeukemiaIndolent Non-Hodgkin LymphomaFollicular Lymphoma+3 more
Gilead Sciences 6
Testing effectiveness (Phase 2)Study completedNCT04298879
What this trial is testing

IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

Who this might be right for
Indolent Non-hodgkin Lymphoma
Innovent Biologics (Suzhou) Co. Ltd. 81
Testing effectiveness (Phase 2)Active Not RecruitingNCT05025800
What this trial is testing

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Who this might be right for
Aggressive B-Cell Non-Hodgkin LymphomaAnn Arbor Stage III Grade 2 Follicular LymphomaAnn Arbor Stage III Grade 3 Follicular Lymphoma+17 more
M.D. Anderson Cancer Center 47
Early research (Phase 1)Study completedNCT01410513
What this trial is testing

Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

Who this might be right for
Indolent Non-Hodgkin LymphomaMantle Cell LymphomaChronic Lymphocytic Leukemia
Sanofi 37
Testing effectiveness (Phase 2)Study completedNCT02207062
What this trial is testing

Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma

Who this might be right for
Recurrent Transformed B-Cell Non-Hodgkin LymphomaRefractory Transformed B-Cell Non-Hodgkin Lymphoma
University of Washington 20
Early research (Phase 1)Active Not RecruitingNCT05665062
What this trial is testing

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

Who this might be right for
CLL/SLLNHLMantle Cell Lymphoma+4 more
Synthekine 36
Testing effectiveness (Phase 2)Study completedNCT01995669
What this trial is testing

Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma

Who this might be right for
Grade 3a Follicular LymphomaRecurrent Follicular LymphomaRecurrent Grade 1 Follicular Lymphoma+7 more
M.D. Anderson Cancer Center 66
Large-scale testing (Phase 3)Ended earlyNCT01077518
What this trial is testing

Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy

Who this might be right for
Lymphoma, Follicular
Novartis Pharmaceuticals 346
Very early researchStudy completedNCT02846935
What this trial is testing

P53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies

Who this might be right for
T-cell LymphomaAggressive B-cell LymphomaNon-Hodgkin's Lymphomas+1 more
Yogen Saunthararajah 7
Testing effectiveness (Phase 2)WithdrawnNCT02653989
What this trial is testing

Efficacy and Safety Study of MDV9300 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Who this might be right for
Lymphoma, Large B-Cell, DiffusePrimary Mediastinal Large B-cell LymphomaTransformed Indolent Lymphoma
Medivation, Inc.
Early research (Phase 1)Study completedNCT01429025
What this trial is testing

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma

Who this might be right for
Refractory/Relapsed Indolent Non-Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology 26
Testing effectiveness (Phase 2)WithdrawnNCT00003663
What this trial is testing

Rituximab and Dexamethasone in Treating Patients With Recurrent or Refractory Indolent Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Hoag Memorial Hospital Presbyterian
Testing effectiveness (Phase 2)Looking for participantsNCT06458439
What this trial is testing

Epcoritamab-CAR T Cells for Large B-cell Lymphomas

Who this might be right for
Lymphoma, Non-HodgkinRelapsed Diffuse Large B Cell LymphomaRefractory Diffuse Large B-cell Lymphoma+2 more
Abramson Cancer Center at Penn Medicine 31
Testing effectiveness (Phase 2)Study completedNCT01994382
What this trial is testing

Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL

Who this might be right for
Follicular Lymphoma (FL/Indolent NHL)Aggressive NHL (a NHL)Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)+2 more
Alexion Pharmaceuticals, Inc. 260
Next Page
24